ESPR – esperion therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Form SC 13G/A Esperion Therapeutics, Filed by: Two Seas Capital LP
Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC
Form SC 13G Esperion Therapeutics, Filed by: BlackRock, Inc.
Form 10-Q Esperion Therapeutics, For: Sep 30
Form 8-K Esperion Therapeutics, For: Nov 07
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.